The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 May 2026•

1 min read

Harmony Biosciences Reports 17% Q1 Revenue Growth, Reaffirms 2026 Billion-Dollar Guidance

Key Facts

1Harmony Biosciences reported Q1 2026 revenue of $215.4 million, representing 17% year-over-year growth for WAKIX.

2The company reinforced its full-year 2026 net revenue guidance of over $1 billion.

Harmony Biosciences Holdings, Inc. reported its financial results for the first quarter of 2026, with total revenue reaching $215.4 million. This performance represents a robust 17% year-over-year growth for its primary product, WAKIX, highlighting strong demand despite typical first-quarter seasonal market access headwinds. Furthermore, the company reaffirmed its full-year 2026 net revenue guidance, maintaining a target of over $1 billion. These results demonstrate the company's financial stability and its ability to effectively navigate market access challenges. Investors are closely monitoring the firm's momentum as it strives to meet its long-term objectives within the biotechnology sector. Continued confidence in WAKIX remains a primary driver for the company's future growth and market expansion.